Differences in Hypercholesterolemia and Atherogenesis Induced by Common Androgen Deprivation Therapies in Male Mice

Journal of the American Heart Association
Christian Bo PoulsenJacob Fog Bentzon

Abstract

Treatment of prostate cancer often involves androgen deprivation therapy (ADT) by gonadotropin-releasing hormone (GnRH) receptor agonists, GnRH receptor antagonists, or orchiectomy. ADT may increase the rate of cardiovascular disease events, but recent clinical studies suggested that not all means of ADT carry the same risk, raising the possibility of non-testosterone-mediated effects of different forms of ADT on atherosclerosis. Here we compared effects of ADT on atherosclerosis in intact and orchiectomized Apoe-deficient mice. Chow-fed Apoe-deficient mice were allocated to orchiectomy and/or monthly injections with the GnRH receptor agonist leuprolide or the GnRH receptor antagonist degarelix. Atherosclerosis was quantified at 26 weeks of age in the aortic arch by en face examination and in the aortic root by histology. In intact Apoe-deficient mice, all types of ADT reduced testosterone production to castration levels. Although hypercholesterolemia was accentuated in leuprolide-treated mice, the amount and composition of atherosclerosis was not different between the different types of ADT. In orchiectomized Apoe-deficient mice, leuprolide, but not degarelix, augmented hypercholesterolemia, changed body, thymus, and spleen we...Continue Reading

References

Jan 1, 1992·Life Sciences·W M van WeerdenF H Schröder
Apr 1, 1996·Cellular and Molecular Neurobiology·L M Garcia-SeguraF Naftolin
Mar 21, 1998·Neuroendocrinology·J D JacobsonR L Wilder
Sep 18, 1998·Cancer·W A SatarianoS K Van Den Eeden
Apr 11, 2001·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·G von DehnA von Eckardstein
Sep 22, 2001·The American Journal of Medicine·E A WhitselD S Siscovick
Feb 28, 2003·Biology of Reproduction·Vishwa Deep DixitRajagopala Sridaran
Mar 13, 2003·The Journal of Endocrinology·F TanriverdiP M G Bouloux
Apr 22, 2005·The New England Journal of Medicine·Göran K Hansson
Apr 25, 2006·Journal of the American College of Cardiology·Erling Falk
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Farin KamangarWilliam F Anderson
Jul 4, 2006·The Journal of Urology·Jennifer YannucciGlenn J Bubley
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy L KeatingMatthew R Smith
Mar 3, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Stephen M SchwartzErling Falk
Apr 25, 2008·Current Protocols in Immunology·Ada M KruisbeekAngela M Thornton
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Dec 5, 2008·Journal of the American Geriatrics Society·Melanie KetchandjiJames S Goodwin
Feb 10, 2009·Nature Clinical Practice. Urology·William P HarrisBruce Montgomery
Apr 22, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gabrielle L GoldbergMarcel R M van den Brink
Feb 4, 2010·Circulation·Glenn N LevineUNKNOWN American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer So
Aug 5, 2010·Current Opinion in Lipidology·Jacob Fog Bentzon, Erling Falk
Jan 1, 2008·CSH Protocols·Joachim Weischenfeldt, Bo Porse
May 20, 2011·Nature·Peter LibbyGöran K Hansson
Jun 17, 2011·Science Translational Medicine·Gaoping ZhaoShaoping Deng
Dec 18, 2012·European Heart Journal·Erling FalkRenu Virmani
Jan 3, 2013·The Journal of Clinical Investigation·Andrew H LichtmanJoseph L Witztum
Jul 12, 2013·Journal of the American Heart Association·Michael J HerringRobert A Kloner
Mar 4, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sean O'FarrellMieke Van Hemelrijck
Mar 11, 2015·European Journal of Clinical Investigation·Matthew L RomoC Mary Schooling

❮ Previous
Next ❯

Citations

Dec 15, 2020·American Journal of Physiology. Endocrinology and Metabolism·Na Ri KimDirk Vanderschueren

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
ELISAs
Assay

Software Mentioned

Prism
ImageJ
GraphPad

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.